Inochem

Inochem is a French contract research organization (CRO) and biotechnology company specializing in medicinal chemistry and the development of therapies targeting the TREM-1 pathway. Based in Nancy, France, the company provides specialized R&D services, including custom synthesis and chemical analysis, to the global pharmaceutical industry. Inochem is most notable for its foundational research into the Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), which led to the establishment of its clinical-stage spin-off, Inotrem. Through this connection, Inochem is associated with the development of nangibotide, a first-in-class TREM-1 inhibitor currently being evaluated in clinical trials for septic shock, COVID-19, and myocardial infarction. The company continues to support drug discovery efforts through its expertise in inflammatory and cardiovascular therapeutic areas.